Preoperative MDCT assessment of resectability in borderline resectable pancreatic cancer: Effect of neoadjuvant chemoradiation therapy

Ijin Joo, Jeong Min Lee, Eun Sun Lee, Su Joa Ahn, Dong Ho Lee, Sun Whe Kim, Ji Kon Ryu, Do Youn Oh, Kyubo Kim, Kyoung Bun Lee, Jin Young Jang

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


OBJECTIVE. The purpose of this study is to evaluate the diagnostic performance of MDCT in assessing tumor resectability in patients with borderline resectable pancreatic cancers after receiving neoadjuvant chemoradiation therapy (CRT) in comparison with those undergoing upfront surgery. SUBJECTS AND METHODS. Thirty-seven patients with borderline resectable pancreatic cancers were randomly allocated to the neoadjuvant CRT group (arm 1; n = 18) or upfront surgery group (arm 2; n = 19). Three radiologists rated the likelihood of local resectability on a 5-point scale at preoperative MDCT in two separate sessions (session 1: post-CRT of arm 1, baseline of arm 2; session 2: using new imaging criteria reflecting the changes during CRT of arm 1). The AUC of each reviewer, as well as sensitivity, specificity, and accuracy based on consensus interpretation, were compared between arms and sessions. RESULTS. For local resectability (n = 30), AUC values at session 1 were 0.664, 0.669, and 0.588 for reviewers 1, 2, and 3, respectively, and were not significantly different between arms 1 (n = 15; 0.759, 0.713, and 0.593) and 2 (n = 15; 0.852, 0.685, and 0.722) (p > 0.05). In arm 1, MDCT sensitivity, specificity, accuracy were 22%, 100%, and 53%, respectively, at session 1 versus 78%, 67%, and 73%, respectively, at session 2 (p > 0.05). CONCLUSION. In patients with borderline resectable pancreatic cancers, neoadjuvant CRT did not significantly decrease the performance of MDCT for the prediction of local resectability. However, by considering post-CRT changes, such as nonprogression in tumor-vascular contact, MDCT may provide better sensitivity for locally resectable disease.

Original languageEnglish
Pages (from-to)1059-1065
Number of pages7
JournalAmerican Journal of Roentgenology
Issue number5
StatePublished - May 2018

Bibliographical note

Funding Information:
Supported by grant HI14C2640 from the Korean Health Technology R&D Project and grant 1120310 from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea.

Publisher Copyright:
© American Roentgen Ray Society.


  • Borderline resectable
  • MDCT
  • Neoadjuvant chemoradiation
  • Pancreatic cancer
  • Resectability


Dive into the research topics of 'Preoperative MDCT assessment of resectability in borderline resectable pancreatic cancer: Effect of neoadjuvant chemoradiation therapy'. Together they form a unique fingerprint.

Cite this